New, more effective and less toxic drugs are needed for children who have relapsed acute lymphoblastic leukaemia (ALL) or are at high risk of relapse. Unfortunately, developing new cancer drugs usually costs millions of pounds and takes many years to reach patients. Rather than create new drugs from scratch, Dr Julie Irving and her team aim to bypass these cost and time constraints by screening ALL cells for potential drug targets and matching them against already existing drugs that are used for other types of cancer but could be repurposed to use against ALL.
Optimising the use of repurposed drugs to improve the treatment of children with ALL
Prof. Julie Irving
Newcastle upon Tyne, NE2 4HH
1 February 2021